ATMPs Publications and Research Funding Opportunities
Research – from early-stage drug discovery through to manufacturing and clinical research – is the life-blood of the rapidly-evolving advanced therapeutics sector. Over recent years Ireland’s research-performing institutes have developed a bedrock of research talent and expertise and are building a portfolio of innovative research projects. In parallel, Ireland has developed a wide range of state research funding sources and supports.
This section of the Advanced Therapeutics Ireland portal pulls together the latest research funding opportunities and highlights the latest ATMP research publications.
Below you will find a selection of Horizon Europe funding calls relevant to advanced therapies. For a complete overview of all calls, please refer to the Horizon Europe Work Programme 2025-2026 document.
Funding Opportunities
-
The Strategic Partnership Programme is a flexible mechanism for academic researchers to build strategic collaborations with key stakeholders such as industry, other funding agencies, charities, philanthropic organisations, higher education institutes (HEIs), or a combination of any of these. The scheme aims to support stand-alone research initiatives of scale with strong potential for delivering economic and societal impact to Ireland, in partnership with key stakeholders.
Funder:
Research IrelandCall Status:
UpcomingUntargeted
-
The US-Ireland Research and Development Partnership is a unique initiative involving funding agencies across three jurisdictions: United States of America, Republic of Ireland & Northern Ireland. The overall goal of the Partnership is to increase the level of collaborative R&D amongst researchers and industry across the three jurisdictions. This collaboration aims to generate valuable discoveries and innovations which are transferable to the marketplace, or will lead to enhancements in health, disease prevention or healthcare.
Funder:
Research IrelandCall Status:
Open – Rolling CallTargeted
-
EPSRC and Research Ireland have an established agreement to welcome, encourage and support research applications that cut across national boundaries involving collaborative teams led by researchers from the UK and Ireland. This Partnership supports joint research and technology development in all areas of EPSRC’s remit which covers chemistry, engineering, information and communications technologies, materials, mathematical sciences and physics.
Funder:
Research IrelandCall Status:
Open – Rolling CallTargeted
-
The Research Ireland Frontiers for the Future Programme provides opportunities for independent investigators to conduct highly innovative, collaborative research with the potential to deliver impact, whilst also providing opportunities for high-risk, high-reward research projects.
Funder:
Research IrelandCall Status:
2024 Call: Projects stream is CLOSED
2024 Call: Awards stream is OPEN Rolling CallUntargeted
-
The Disruptive Technologies Innovation Fund (DTIF) is a €500 million challenge-based fund established under Project Ireland 2040. It is one of four funds set up under the National Development Plan (NDP) 2018-2027. It is managed by the Department of Enterprise, Tourism and Employment and administered by Enterprise Ireland.
DTIF is suitable for combinations of SMEs, MNCs and RPOs who are engaging in collaborative ‘industrial research’ and/or ‘experimental development’ towards a common objective.
You should apply to DTIF if your project will potentially:
- alter markets
- alter the way businesses operate
- involve the creation of new products or
contribute to the emergence of new business models
Projects are assessed based on four criteria:
- strength of the disruptive technology dimension
- excellence of the overall proposal and approach
- economic impact and sustainability
- quality and efficiency of the collaboration
There are a number of key changes for Call 8:
- €40 million funding budget available for Call 8, with projects funded according to their ranking based on weighted evaluation scores
- Call 8 has a fixed application window of four months, with all applications assessed after the deadline of 3 February 2027 at 3pm Irish Time
- Irish Semi-State organisations and public bodies are now eligible to participate as non-funded partners, provided projects still include at least three other eligible partners
- Mandatory pre-eligibility check introduced for all applicants before submitting a proposal
- Reduced project commencement timeline, with projects expected to start within 6 months of the Ministerial announcement of award
Call 8 was announced on 9 June 2026 and opened for applications on 1 October 2026.Funder:
Enterprise Ireland
Call Status: Open
Call Deadline: 3 February 2027Untargeted
-
This funding programme encourages Irish-based companies to work with Irish researchers to undertake research which supports the development of new and improved products, processes, services and generate new knowledge and know-how.
Funder:
Enterprise IrelandCall Status:
Call OPEN (multiple cut-offs per year)Untargeted
-
Destination 5 – Developing and using new tools, technologies and digital solutions for a healthy society
Tissue-specific functional 3D bio-printing of living cells has made significant progress as a new approach for transplantation applications in regenerative medicine. There are currently several types of bio-printing technologies under development for the repair of different targeted tissues or organs. To fully unleash the potential of bio-printed cell constructs for regenerative medicine several bottlenecks still need to be overcome. Various studies in pre-clinical models have shown that bio-printed cell constructs or tissues hold great
promise for regenerative medicine, by allowing autologous tissue grafts being printed thus avoiding adverse graft-host reactions. However, translation of such approaches into clinical settings (i.e. humans) and their application to internal organs still needs to be investigated and demonstrated.Funder
Horizon EuropeCall Opening : 3 June 2027
Call Deadline : UpcomingTargeted -
The ERC Consolidator Grant supports excellent researchers who are consolidating their independent research teams or programmes and have already demonstrated research independence.
The grant is open to Principal Investigators who successfully defended their PhD between 1 January 2012 and 31 December 2021 (inclusive), subject to applicable eligibility extensions.
Researchers who have previously received an ERC Starting or Consolidator Grant cannot apply again for the same type of grant. Additional eligibility and resubmission restrictions may apply.
Funder
Horizon EuropeCall Opening : 24 September 2026
Call Deadline : 12 January 2027Targeted -
HORIZON-HLTH-2027-01-IND-01
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Maintaining an innovative, sustainable, and competitive EU health industry”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:Biopharmaceutical industries get access to streamlined development and production processes for peptide- or protein-based biologicals.
Health systems benefit from the availability of enhanced or decentralised production systems for innovative health technologies that involve peptides or proteins, and which improve health and care.
Citizens and patients will benefit from better access, availability and affordability of pharmaceuticals based on biologicals.Funder
Horizon EuropeCall Opening : 29 October 2026
Call Deadline : 17 February 2027Targeted -
HORIZON-HLTH-2027-01-DISEASE-06
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:The scientific and clinical communities have a better understanding of and access to experimental monoclonal antibodies for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation.
Candidate monoclonal antibody therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.
Funder
Horizon EuropeCall Opening : 29 October 2026
Call Deadline : 17 February 2027Targeted -
HORIZON-HLTH-2027-01-DISEASE-07
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:The scientific and clinical communities have a better understanding of and access to experimental monoclonal antibodies for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation.
Candidate monoclonal antibody therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.
Funder
Horizon EuropeCall Opening : 29 October 2026
Call Deadline : 17 February 2027Targeted
Publications
-
Increased-functional-potency-of-multi-edited-CAR-T
Avectas, Cherrywood Business Park - Dublin, Ireland; University College London, Cancer Institute - London, UKDate: -
Why Ireland for Cell and Gene Therapy Development and Manufacturing
IDA IrelandDate: -
The Case for Cell and Gene Therapy Manufacturing in Ireland
The CGT Forum membersDate: -
AAV-mediated gene therapy improving mitochondrial function provides benefit in age-related macular degeneration models
Sophia Millington-Ward, Naomi Chadderton, Laura K. Finnegan, Iris J.M. Post, Matthew Carrigan, Tom Gardiner, Elisa Peixoto,Daniel Maloney, Marian M. Humphries, Alan Stitt, Thierry Léveillard, Pete Humphries, Paul F. Kenna, Arpad Palfi, G. Jane FarrarDate: -
CGT Forum Working Group 7 Report 2022
Drafted by Cormac Kennedy; Reviewed by Working Group 7Date: -
Proteomic Landscape of Adeno-Associated Virus (AAV)-Producing HEK293 Cells
Lisa Strasser, Stefano Boi, Felipe Guapo, Nicholas Donohue, Niall Barron, Alana Rainbow-Fletcher, Jonathan BonesDate: -
The Regulatory Landscape for ATMPs in the EU and US: a Comparison
Shada Warreth, Elaline HarrisDate: